News & Updates

New data support B/FTC/TAF use in HIV+ children

Data from a French study presented at CROI 2023 support the use of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/FTC/TAF) in the management of paediatric patients with HIV.

Rifaximin helps improve symptoms of IBS with diarrhoea

Treatment with rifaximin appears to produce significant reductions in multiple, concurrent symptoms of irritable bowel syndrome (IBS) with diarrhoea, according to a study that uses a novel tri-symptom endpoint.

Bempedoic acid cuts CV events in statin-intolerant patients

The use of bempedoic acid significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with high cholesterol who are intolerant to statins in the phase III CLEAR* Outcomes trial presented at ACC.23/WCC.

ICD maintains shock function after MRI

Non-magnetic resonance imaging (MRI)-conditional implantable cardioverter defibrillators (ICDs) are effective at treating detected tachyarrhythmias after MRI, with no serious adverse effects on device function seen, reports a study.

High iron level ups risk of noncommunicable disease in adolescents

A recent study in India has found a significant association between high serum ferritin (SF) and noncommunicable disease (NCD) in adolescents. Additionally, such interaction is dependent on wealth and coexisting prediabetes.

Long-term OLE boosts potential of remibrutinib for CSU

In the 52-week open-label extension (OLE) of a phase IIb study presented at AAAAI 2023, the BTK* inhibitor remibrutinib demonstrated sustained efficacy and a favourable safety profile for the treatment of chronic spontaneous urticaria (CSU).

GLP-1 RA Diabetes Mellitus Type 2 Diabetes Management Dulaglutide